(Renal Cell Carcinoma) Is Keytruda Plus Inlyta Effective? KEYNOTE-426 5-Year Follow-Up Results
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
- July 5, 2023
- 1 min read
At ASCO 2023, held in Chicago from June 2–6, 2023, Brian I. Rini and colleagues from Vanderbilt-Ingram Cancer Center presented 5-year follow-up results from the KEYNOTE-426 Phase 3 clinical trial evaluating the efficacy and safety of pembrolizumab (Keytruda) plus axitinib (Inlyta) in treatment-naive renal cell carcinoma patients.
Trial Design:
The KEYNOTE-426 Phase 3 trial randomized treatment-naive renal cell carcinoma patients (N=861) 1:1 to:
- Pembrolizumab 200 mg + axitinib 5 mg twice daily (3-week cycle, N=432)
- Sunitinib (Sutent) 50 mg once daily
Primary endpoints were PFS and OS.
Results at median follow-up of 67.2 months:
| Endpoint | Keytruda + Inlyta | Sutent |
|---|---|---|
| 5-year OS rate | 41.9% | 37.1% |
| 5-year PFS rate | 18.3% | 7.3% |
| Median duration of response | 23.6 months | 15.3 months |
Safety:
Treatment discontinuation rate: Keytruda + Inlyta 62.2% (237/381 patients) vs. Sutent 73.9% (300/406 patients). No new safety signals were identified.
Conclusion: Based on the KEYNOTE-426 5-year follow-up analysis, Brian I. Rini and colleagues concluded that Keytruda plus Inlyta demonstrated improved 5-year OS and PFS compared to Sutent monotherapy in treatment-naive renal cell carcinoma patients, supporting its continued use as a standard of care.
Source: https://meetings.asco.org/abstracts-presentations/219855
Renal Cell Carcinoma | Immunotherapy | Keytruda | Inlyta | KEYNOTE-426
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4